Ensysce Biosciences (NASDAQ:ENSC) Price Target Cut to $8.00 by Analysts at Lake Street Capital

Ensysce Biosciences (NASDAQ:ENSCGet Rating) had its price target decreased by Lake Street Capital to $8.00 in a research report sent to investors on Thursday, Stock Target Advisor reports. Lake Street Capital currently has a buy rating on the stock.

Ensysce Biosciences Price Performance

Shares of Ensysce Biosciences stock opened at $2.05 on Thursday. The business has a 50-day moving average of $0.99 and a 200 day moving average of $0.70. Ensysce Biosciences has a 12 month low of $1.90 and a 12 month high of $140.00. The stock has a market capitalization of $3.93 million, a price-to-earnings ratio of -0.10 and a beta of 0.19.

Ensysce Biosciences Company Profile

(Get Rating)

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology.

Recommended Stories

Receive News & Ratings for Ensysce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ensysce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.